Incisive Technologies is a dental company focussed on empowering oral healthcare professionals and increasing the opportunity for preventive treatments globally.

It is widely recognized that accurate, early detection will help reduce the incidence and impact of tooth decay, what is a widespread yet preventable chronic disease. However, while other detection tools are available, they have not been widely adopted – for a range of reasons including large capital expense, complex equipment, time-consuming procedures and insufficient sensitivity.

Developed as a direct measure of disease

The technology is the result of collaboration between Incisive Technologies and The University of Melbourne, well-known for innovations in oral health, with the express purpose of improving clinical outcomes for dental patients.

The lead technology used in BlueCheck came out of research conducted at the University of Melbourne by enamel expert and our Chief Scientific Officer Dr Jonathan Mangum. He was seeking a solution to a problem known as ‘chalky teeth’, which is faced by 1 in 10 young children. This discovery led to an understanding that protein has a high affinity for porous enamel, which is the fundamental definition of caries and the precursor to dental cavities. 

This research led to the development of a specifically designed biomolecule, consisting of a protein molecule linked with a dye, that targets areas of the tooth surface at their earliest stage of demineralization. We have created a direct measure of disease as visible cue and to provide dental professionals with the objective evidence of disease.

Advancing oral healthcare by enabling preventive healthcare 

Incisive Technologies aim is to advance oral healthcare by enabling preventive dentistry. It has R&D programs to develop its product pipeline in oral care and is committed to a long-term mission to equip oral healthcare professionals with the tools they need to address the global challenge of tooth decay. Incisive will continue to drive innovation through strong science and with outstanding partners. BlueCheck is an important first step in this mission.

Company growth has been significant in recent years, facilitated by a passionate team, a successful partnership with CareQuest Innovation Partners (Boston), the leading dental advocacy group in the US, and an AusIndustry Accelerating Commercialisation grant. These have propelled Incisive towards translation and scale-up readying for commercialisation and entry into the US Market following FDA 510k Clearance in 2023.

BlueCheck is the first product to be commercialised by Incisive Technologies. We are committed to advancing improved caries management and will continue to work with leading clinicians and academics to support the drive towards prevention and minimally invasive care. Incisive has a number of research and collaboration projects to understand BlueCheck’s role in clinical management and how it can make early caries detection simple.